<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>16158783</identifier>
<setSpec>0002-5151</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Rodríguez Orozco, Alain R</dc:author>
<dc:author>Serriteño, Nicolas Medina</dc:author>
<dc:description xml:lang="en">In the last few years we have witnessed a reorientation process in the diagnosis and treatment of cancer, and advances in cancer research point to the need for selective or specific immunomodulation therapies. In this article we remark on generalities of the immune response against tumors, highlighting both: mechanisms that underlie immune evasion by tumors and host defense mechanisms against malignancies. We also discuss current experience with the use of biological response modifiers in cancer and of immunomodulation therapies, in terms of accumulated effectiveness and adverse events of new biological response modifiers. We conclude that therapies with BRMs are hopeful and effective strategies to treat cancer, either alone or in combination with chemotherapy, surgery or radiations. Immunomodulation seem to be one of the most promising therapies for the control of malignant diseases.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2005 Mar-Apr </dc:date>
<dc:title xml:lang="es">La inmunomodulación en cáncer. Que hacemos y hacia dónde vamos?</dc:title>
<dc:title xml:lang="en">[Immunomodulation in cancer. What do we do and where do we go?].</dc:title>
<dc:publisher>Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)</dc:publisher>
</metadata>
</record>
</pubmed-document>
